Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941338 | 0.85 | SMO (0.47) | EPHX2HRH3SMOF10LMNA | |
| SCHEMBL4941341 | 0.70 | SMO (0.47) | HRH3SMOF10SMN1; SMN2 | |
| SCHEMBL4941337 | 0.70 | SMO (0.47) | HRH3SMOF10SMN1; SMN2 | |
| SCHEMBL9214671 | 0.65 | HRH3 (0.46) | EPHX2HRH3SMO | |
| SCHEMBL9219478 | 0.63 | HRH3 (0.47) | HRH3SMO | |
| SCHEMBL9220710 | 0.63 | HRH3 (0.45) | EPHX2HRH3SMO | |
| SCHEMBL21626550 | 0.63 | HRH3 (0.52) | HRH3SMOLMNASMN1; SMN2 | |
| SCHEMBL15548336 | 0.63 | HRH3 (0.54) | EPHX2HRH3SMOLMNA | |
| SCHEMBL4890873 | 0.60 | LMNA (0.55) | HRH3SMOLMNA | |
| SCHEMBL31514107 | 0.58 | HRH3 (0.48) | EPHX2HRH3MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | EPHX2 1143/4885HRH3 31/4885PARP1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.